DocumentsDate added
Original article
M. Sakthibalan1,*,Maruti Sripati Sawadkar1,¥
Affiliation:
1Assistant Professor,1,¥Retired Professor, Department of Pharmacology, Sri Venkateshwara Medical College Hospital & Research Centre, Pondicherry University, Pondicherry, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Pharmacology, Sri Venkateshwara Medical College Hospital & Research Centre, Pondicherry University, Pondicherry, India
Address reprint requests to
Dr.Murugesan Sakthibalan,
Assistant Professor,
Department of Pharmacology,
Sri Venkateshwara Medical College Hospital& Research Centre, Ariyur, Pondicherry, India - 605102
Article citation:
Sakthibalan M, Sawadkar MS. To evaluate the anti-cancer effect of Doxorubicin when given in combination with cardioprotective agents like N-acetlycysteine, Enalapril and Vitamin c in Ehrlich ascites tumor induced adult wistar rats. J Pharm Biomed Sci. 2015; 05(04):300-307. Available at www.jpbms.info
ABSTRACT:
Background: The anthracycline antibiotic, Doxorubicin has beenproved very effective in a broad range of haematogenous and solid human malignancies. Its use is limited by its irreversible degenerative cardiomyopathy. This has driven us to find novel treatment modalities to reduce its cardiac side effects without conceding its anti-cancer effect.
Objective: To evaluate the anti cancer effect of Doxorubicin when given in combination with cardioprotective agents like N-acetlycysteine, Enalapril and Vitamin c in Ehrlich ascites tumor inducedwistar rats.
Methodology: The male adult wistar rats selected for investigate, divided into six groups with six rats in each group. Rats bearing Ehrlich ascites tumor were selected for the study. The rats in the control group and toxic control were administered sterile water and Doxorubicin respectively on day 5. N-Acetylcysteine, Enalapril and Vitamin c administered orally for seven days as dual drug and triple drug combinations. On day seven, the rats were sacrificed and blood was collected for estimation of cardiac stress markers and cardiac tissue was sent for histopathological estimation. The Peritoneal fluid was aspirated and the volume and viable tumor cell count assessed, using trypan blue exclusion technique. Statistical Analysis: Student ‘t’ test and one way ANOVA followed by Bonferroni test is applied.
Result and conclusion: The tumor volume and cell count at the end of the experiment was measured and it was found out that the anti-cancer effect of doxorubicin is not compromised on instilling various cardioprotective drugs in various combinations to treat doxorubicin induced cardiotoxicity.
KEYWORDS: Doxorubicin, Ehrlich ascites tumor, Trypan blue, N-Acetylcysteine, Enalapril, Vitamin C.
A part of the Manuscript was presented at: International and Annual Conference of Indian Pharmacological Society (IPSCON),Nagpur, India, on January 6th 2013.
REFERENCES
1.Olson RD, Mushlin P. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990;4:3076–86.
2. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med.1996;125:47–58.
3.Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900–905.
4.Ozaslan M, Karagoz ID, Kilic IH and Guldur ME.Ehrlich ascites carcinoma. African Journal of Biotechnology. Vol. 10(13):2375-78.
5. Sakthibalan M, Sawadkar MS, Asmathulla S, Ivan EA, Muthu G. Study of cardio protective effect of NAcetylcysteine,Vitamin C and Enalapril given in combination to prevent doxorubicin induced cardio toxicity in Wistar rats. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 November 36(36):1902-1908. Accessed from www.jpbms.info.
6. Stroud AN, Brues AM, Chatterley DH, et al. Serial Transplantation of Krebs-2 and Ehrlich Ascites Tumors to Rats. Cancer Res 1957;17:1102-1107.
7.Sakthibalan M, Rameshprabu S, Nileshraj G, Rameshkannan S, Ivan EA, Sawadkar MS. To Study the Chemotherapeutic Effect of Doxorubicin When Combined With Aspirin and Clopidogrel in Ehrlich Ascites Carcinoma Induced Adult Wistar Rats. International Journal of Recent Trends in Science and Technology, Volume 9, Issue 2, 2013; 218-220.
8.Pathan RA, Singh BK, Pillai KK and Dubey K.Naproxen aggravates doxorubicin-induced cardiomyopathy in rats. Indian J Pharmacol. 2010; 42(1): 44–49.
9.Ivanovski O, Szumilak D, Khoa TN, Ruellan N, Phan O, Lacour B, Latscha BD, Drueke TB and Massy ZA. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney International.2005; 67: 2288–94.
10.Abd El-Aziz MA, Othman AI, Amer M, El-Missiry MA. Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. Journal of Applied Toxicology. Vol. 21(6):469–473.
11. Santos RV, Batista Jr ML, Caperuto EC, Costa Rosa LF. Chronic supplementation of creatine and vitamins C and E increases survival and improves biochemical parameters after Doxorubicin treatment in rats. Clin Exp Pharmacol Physiol. 2007;34(12):1294-99. 12. Tietz, NW, Fundamentals of clinical chemistry, W.B. Saunders co., Philadelphia,1976.
13.German society for clinical chemistry: Recommendations of the Enzyme Commision. J.Clin.Chem.Clin.Biochem.1997;15:255.
14.Anderson ME. Enzymatic and chemical methods for the determination of glutathione. In: Dolphin D, editor. Glutathione. 1st vol. New York: John Wiley and Sos; 1983.340–65.
15. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95: 351-8.
16.Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem. 1986;261:3060–67.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of funding: None
Competing interest / Conflict of interest: The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Sakthibalan M, Sawadkar MS. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Nirmalya Nirbisank1,*, Ranjit Kumar Mishra1,¥
Affiliation:
1P.G Student,1¥Professor and HOD Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
The name of the department(s) and institution(s) to which the work should be attributed:
Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Address reprint requests to
* Dr Nirmalya Nirbisank.
3rd, P.G Student, Department of General surgery, Hi-Tech Medical College and Hospital, Bhubaneswar, Odisha, India
Article citation:
Nirbisank N, Mishra RK. Amylase creatinine clearance ratio in post-operative patients for evaluation of acute pancreatitis. J Pharm Biomed Sci. 2015; 05(04):296-299. Available at www.jpbms.info
ABSTRACT:
Background: Post operative pancreatitis is a well known complication of biliary tract operations,particularly following supraduodenal exploration of the common bile duct and transduodenal sphincterotomy.Although this event occurs in a relatively small number of patients following these procedures,it is an event that should be avoided whenever possible.It is found that the diagnostic value of amylase measurements may be enhanced if amylase excretion is related to creatinine excretion.
Material and Methods: It is a study conducted on the amylase creatinine clearance ratio in post operative patients for evaluation of pancreatitis..The data collected for our study included patients from Hitech medical college and hospitals, Bhubaneswar,Odisha, India during the period from August 2012 to November 2014.
Results: The study was conducted on sixty cases who were posted for surgery for at Hitech medical college and hospital Bhubaneshwar,Odisha,India. They were divided in to two groups of thirty cases each depending on the surgeries involved.
Conclusion: In this present study we assess the changes in the level of amylase creatinine clearance ratio in the post operative period and its value in the diagnosis of post-operative pancreatitis.
KEYWORDS: Pancreatitis; Serum amylase; Amylase creatinine clearance ratio.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
REFERENCES
1.Demols A, Daviere J New frontiers in the pharmacological prevention of post-ERCP pancreatitis: the cytokines. J.P. 2003 Jan: 4(1): 49-57.
2.Donaldson LA, Melntosh W, Joffe S.N. Amylase creatinine clearance ratio after biliary surgery Gut 2009;
18: 16-18.
3.Dreiling DA, Leichtling JJ and Ianowitt HD. The ACCR. Amer J Gastroenterol 2007; 61: 290-296.
4.Duane WC, Frerichs R, Levitt MD. Distribution, turnover and mechanism of renal excretion of amylase in the baboon. J clin Invest 2004;50:156-165.
5.Ellis C, Kochler DF, Eckfaldt JH, Levitt MD. Evaluation of an to determine serum isoamylase distribution. Dig Dis Sci 2010; 27: 897-901.
6.Farrar WH, Calkine WG. Sensitivity of the amylase creatinine clearance ratio in acute pancreatitis. Arch Intern Med 2012; 138; 958.
7.Fernandez-del Castillo C, Harringer W, Warshaw AL et al, Risk factors for pancreatic cellular injury after cardiopulmonary by pass N Engl J Med 2013:325:382-387.
8.Folin. Estimation of creatinine. J Biol Chem; 39:81; 1919 or as given in Hawk’s Physiological Chemistry by Oser (1965).
Source of support: None
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Nirbisank N, Mishra RK. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Yanka Karamalakova1,*, Krishna Chuttani2, Rakesh K. Sharma3, Veselina Gadjeva4, Antoaneta Zheleva5 and Anil K. Mishra6
Affiliation:
1. Assistant professor*; Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
2. Assistant professor; Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences,Brig. S.K Mazumdar Marg, Delhi-110054, India
3. Professor; Institute of Nuclear Medicine and Allied Sciences, Brig S. K. Mazumdar Marg, Delhi-110054, India
4.Professor; Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
5. Professor; Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
6.Professor; Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences,Brig. S.K Mazumdar Marg, Delhi-110054, India
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Chemistry and Biochemistry, Medical Faculty, Trakia University, 11 Armeiska Str., 6000 Stara Zagora, Bulgaria
2. Division of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Brig. S.K Mazumdar Marg,Delhi-110054, India
Address reprint requests to
Yanka Karamalakova
Scientist and Assistant Professor, Electron Paramagnetic Resonance Laboratory, Department of Chemistry and Biochemistry, Str Armaiska 11, Medical Faculty, Trakia University, Stara Zagora- 6000, BULGARIA
Article citation:
Karamalakova Y, Chuttani K, Sharma R, Gadjeva V, Gadjeva A, Mishra A. Nitroxyl-Labeled Glycine Containing 2-Chlorethylnitrosourea: A study of 99mTc-Radiolabeling, EPR spectroscopy and biological evaluation of new potential anticancer agent for tumor imaging and radiotherapy. J Pharm Biomed Sci. 2015; 05(04):317-327. Available at www.jpbms.info
ABSTRACT:
Recently, a new class of in vitro and ex vivo radiotracers/radioprotectors, the nitroxyl–labeled agent N-[N'-(2-chloroethyl)-N’-nitrosocarbamoyl-glycine amide of 2,2,6,6-tetramethyl-4-aminopiperidine-1-oxyl (SLCNUgly), has been discovered. Our previous investigations demonstrated that SLCNUgly is a low-molecular-weight stable free radical which is freely membrane permeable, easily crosses the blood brain barrier and exhibited in/ex vivo the lowest general toxicity and higher anticancer activity against some experimental tumor models. Further investigation was aimed to develop a 99mTc-labeled SLCNUgly (96.5%) as a chelator and evaluate its labeling efficiency and potential use as a tumor seeking agent and for early diagnosis. Tissue biodistribution of 99mTc- SLCNUgly was determined in normal mice at 1, 2, and 24 h (n=4/ time interval, route of administration i.v.). The distribution data was compared to that using male albino non-inbred mice and EPR investigation. The imaging characteristics of 99mTc– SLCNUgly conjugate examined in Balb/c mice grafted with Ehrlich Ascitis tumor in the thigh of hind leg demonstrated major accumulation of the radiotracer in organs and tumor. Planar images and auto-radiograms confirmed that the tumors could be visualized clearly with 99mTc- SLCNUgly. Blood kinetic study of radio-conjugate showed a biexponential pattern, as well as quick reduced duration from the blood circulation. This study establishes Glycine Containing nitroxyl (SLCNUgly) as a new spin-labeled diagnostic marker which reduce the negative lateral effects of radiotherapy and for tumor- localization.
KEYWORDS: SLCNUgly, Ex Vivo EPR, 99mTc-conjugate, Biodistribution, EAT Tumor Imaging
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
Source of support: The research work was funded by the Institute of Nuclear Medicine and Allied Sciences, New Delhi, India (BIn–7/2008).
REFERENCES
1. Eary JF, Press OW. High dose radioimmunotherapy in malignant lymphoma. Recent Results Cancer Res. 1996; 141:177–182.
2. De Nardo G, Malik E, Whitec CA, Wisemand G, De Nardoa S. Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing. Crit Rev Oncol Hematol. 2001; 39 (1-2): 203-218.
3. Humblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, Bernhardr SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004; 10: 7063-7070.
4.Theobald AE. Theory and practice. Sampson CB, ed. Text-book of Radiopharmacy. New York, NY: Gorden and Breach. 1990; 127-128.
5. Saha GB. Methods of radiolabeling. Physics and Radiobiology of Nuclear Medicine. New York, NY: Springer-Verlag. 1993; 100-106.
6. Liu S, Edwards DS. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev. 1999; 99: 2235-2268.
7. Arulsudar N, Subramanian N, Mishra P, Chuttani K, Sharma RK, Murthy RSR. Preparation, Characterization, and Biodistribution Study of Technetium-99m -Labeled Leuprolide Acetate-Loaded Liposomes in Ehrlich Ascites Tumor-Bearing Mice. AAPS Pharm Sci. 2004; 6(1): Article 5;1_12.
8. Chuttani K, Mishra P, Chopra M, Panwar P, Sharma RK, Mishra AK. Radiolabelling and Biological Evaluation of a non—peptidic compound from Terminalia chebula (Harar) for CCK Expressing Tumours. IJNM. 2003; 18: 19-24.
9. Gadzheva V, Zheleva A, Raikova E. Modulating effect of new potential antimelanomic agents, spin-labeled triazenes and nitrosoureas on DOPA-oxidase activity of tyrosinase. Cancer Biochem Biophys. 1999; 17(1-2): 99-108.
10. Gadzheva V, Koldamova R. Spin-labeled 1-alkyl-1–nitrosourea synergists of antitumor antibiotics. Anti-cancer Drug Design. 2001; 16 (4-5): 247-253.
11.Tang Wei-Ci and Eisenbrand G. Synthesis of potentialantineoplastic derivatives 0f N-[N-(2-chloroethyl)-N’-nitrosocarbamoyl]-amino asids. Arch. Pharm. (Weinhein). 1981; 314: 910-917.
12. Tsujihara K, Ozeki M, Morikawa T, Kavamori M, Akaike Y, and Arai Y. A new class of nitrosoureas. Synthesis and antitumor activity of disaccharide derivatives of 3,3-disubstituted 1-(2-chloroethyl)-1-nitrosoureas. J.Med. Chem. 1982; 25: 441-446.
13. Berger MR, Floride J, Schreiber J, Schmähl D, and Eisenbrand G. Short term anticancer efficacy in methyl nitrosourea induced rat mammary carcinoma and hormonal activity in mice. Cancer Res. Clin. Oncol. 1984; 108: 148-153.
14. Roger P, Monneret C, Fournier JP, Choay P, Garnet R, Gosse Ch, Letourneux Y, Atassi Ch, Gouyette A. Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars. J. Med Chem. 1989; 32(1): 16-23. 15. Konieczny M, Sosnovsky G, Gutierrez P. In the search for new anticancer drugs, I. Antitumor activity of various nitroxyl- and aziridine-containing phosphorus compounds. Z. Naturforsch. 1981; 36b: 888-891.
16. Gutierrez P., Konieczny M., Sosnovsky G., In the search for new anticancer drugs, II. Antitumor activity, toxicity and electron spi n resonance of spin labeled Thio TEPA derivatives. Z. Naturforsch., 1981; 36b: 1612-1617.
17. Raikov Z., Todorov D., Ilarionova M., Demirov G., Tsanova T., Kafalieva D. Synthesis and study of spin-labeled nitrosoureas. Cancer Biochem Biophys. 1985; 7(4): 343-348.
18. Sosnovsky G, Li SW. In the search for new anticancer drugs XII. Synthesis and biological evaluation of spin labelled nitrosoureas. Life Science, 1985; 36 (15): 1479-1483.
19. Zheleva A, Raikov Z, Ilarionova M, and Todorov D. Spin labeled amino acid nitrosourea derivatives - synthesis and antitumour activity. Pharmazie. 1995; 50: 25-26.
20. Zheleva A, Raikov Z, Ilarionova M, Carpenter B, Todorov D, Armstrong N. Potential antimelanomic drugs 1. Synthesis and antimelanomic effect of a spin labeled D,L-amino acid containing a 2-chloroethylnitrosocarbamoyl group. Pharmazie. 1996; 51: 602-604.
21. Gadjeva V, Raikov Z. Syntheses and antitumor activity of 4-{N-[N-(2-chloroethyl)-N-nitrosocarbamoyl]hydrazono}-2,2,6,6-tetramethylpiperidine-1-oxyl. Die Pharmazie. 1999; 54(13) 79.
22. Zheleva A, Gadjeva V. Spin-labeled nitrosoureas and triazens and their nonlabeled clinically used analogues- a comperative study on their physicochemical properties and antimelanomic effecst. Int. J. Pharmaceutics. 2001; 212: 257- 266.
23. Gadjeva V, Ichimory K, Nakazawa H, Raikov Z. Superoxide scavenging activity of spin-labeled nitrosourea and triazene derivatives. Free Radical Res. 1994; 21(3): 177-186.
24. Ilarionova MV, Zheleva AM, Raikov ZD, Todorov DK, Dudov AP. Nitrosourea antitumor agents correlation between antitumor action and some biochemical properties of newly synthesized derivatives. J. Chemotherapy. 1993; 5 (N1): 786-787.
25. Zheleva A, Stanilova S, Dobrva Z, Zhelev Z. Two glycine containing 2-chloroethylnitrosoureas - a comperative study on some physicochemical properties, in vivo antimelanomic effects and immunomodulatory properties. Int. J. Pharmaceutics. 2001; 222: 237- 242.
26. Matsumoto K, Hyodo F, Matsumoto A, Koretsky AP, Sowers AL, Mitchell JB, and Krishna MC. High resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin Cancer Res. 2006; 12: 2455–2462.
27. Zweier JL, Kuppusamy P. Electron paramagnetic resonance measurements of free radicals in the intact beating heart: a technique for detection and characterization of free radicals in whole biological tissues. Proc. Natl. Acad. Sci. 1988; 85: 5703–5707.
28. Zhelev Z, Bakalova R, Aoki I, Matsumoto K, Gadjeva V, Anzai K, Kanno I. Nitroxyl radicals as low toxic spin-labels for non-invasive magnetic resonance imaging of blood-brain barrier permeability for conventional therapeutics. Chem Commun (Camb). 2009; 7:53-55.
29. Chen XJ, Li L, Liu F, Liu BL. Synthesis and biological evaluation of technetium-99m labeled deoxy glucose derivatives as imaging agents for tumor. Med. Chem. Lett. 2006; 16: 5503-5506.
30. Ilgan S, Yang DJ, Higuchi T, Zareneyrizi F, Bayhan H, Yu D, Kim EE, Podoloff DA. 99mTc-ethylenedicysteine- folate: A new tumor imaging agent, synthesis, labeling, and evaluation in animals. Cancer Biother Radioph. 1998; 6: 427.
31. Richardson VJ, Jeyasingh K, Jewkes RF. Properties of [99mTc] technetium labeled liposomes innormal and tumor bearing rats. Biochem Soc Trans. 1977; 5: 290-291.
32. Halpern HJ, Spencer DP, Polen JV, Bowman MK, Nelson AC, Dowey EM, Teicher BA. Imaging radio frequency electron spin resonance spectometer with high resolution and sensitivity for in vivo mesurements. Rev Sci Instrum. 1989; 60: 1040–1050.
33. Simeonova M, Ivanova T, Raikov Z, Konstantinov H. Tissue distribution of polybutylcyanoacrylate nanoparticles loaded with spin-labeled nitrosourea in Lewis lung carcinoma-bearing mice. Acta Physiol Pharmacol Bulgaria. 1994; 20: 77-82.
34. Gadjeva V, Lazarova G, Zheleva A. Spin labeled antioxidants protect bacteria against the toxicity of alkylating antitumor drug CCNU. Toxicol. Lett.2003; 144: 289-294.
35. Zheleva A, Tolekova A, Goicheva P. Determination of LD50 of potential antitumor agent SLCNUgly and its effect on antioxidant enzyme defense in vivo. Trakia J Sci. 2008; 6(2): 49-53.
36. Gannon MC, Nuttall JA, and Nuttall FQ. Oral arginine does not stimulate an increase in insulin concentration but delays glucose disposal. Am. J. Clin. Nutr. 2002; 76: 1016–1022.
37. Keana JF, Pou S, Rosen GM. Nitroxides as a potentioal contrast enhancing agents for MRI application: influence of structure on the rate of reduction by rat hepatocytes, whole liver homogenate, subcellular fractions, and ascorbate. Magn Reson Med. 1987; 5: 525-536.
38. Zhelev Z, Bakalova R, Aoki I, Matsumoto K, Gadjeva V, Anzai K, Kanno I. Nitroxyl radicals for labeling of conventional therapeutics and noninvasive magnetic resonance imaging of their permeability for blood-brain barrier: relationship between structure, blood clearance, and MRI signal dynamic in the brain. Mol Pharm. 2009; 6: 504-512.
39. Hyodo F, Chuang KH, Goloshevsky AG, Sulima A, Griffiths GL, Mitchell JB, Koretsky AP, Krishna MC. Brain redox imaging using blood - brain barrier - permeable nitroxide MRI contrast agent. J Cereb Blood Flow Metab. 2008; 28: 1165-1174.
40. Hahn SM, Krishna CM, Mitchell JB. New directions for free radical cancer research and medical applications. Adv Exp Med Biol. 1994; 366: 241- 251.
41. Wilcox CS. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol. Ther. 2010; 126(2): 119-145.
42. Hahn SM, Krishna CM, Samuni A, Cuscela DO, Johnstone P, Mitchell JB. Potential use of nitroxides in radiation oncology. Cancer Res. 2004; 54: 2006-2010.
43. Sano H, Naruse M, Matsumoto K, Oi T, Utsumi H. A new nitroxyl-probe with high retention in the brain and its application for brain imaging. Free Radic Biol Med. 2000; 28: 959-969.
44. Zhelev Z, Matsumoto K, Gadjeva V, Bakalova R, Aoki I, Zheleva A, Anzai K. EPR signal reduction kinetic of several nitroxyl derivatives in blood in vitro and in vivo. Gen Physiol Biophys. 2009; 28: 356-362.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Karamalakova Y,Chuttani K,Sharma R,Gadjeva V,Gadjeva A,Mishra A. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Suprita Gupta1, Archana Jayan2 , Amit Chandra Jha2¥, Narayan Gautam2*
Affiliation:
1Associate Professor, Department of Biochemistry, National Medical College Teaching Hospital, Birgunj, Nepal
2Associate Professor,2¥Lecturer, Department of Biochemistry, Universal College of Medical Sciences, Bhairahawa, Nepal
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Biochemistry, National Medical College Teaching Hospital, Birgunj, Nepal
2.Department of Biochemistry, Universal College of Medical Sciences, Bhairahawa, Nepal
Address reprint requests to
* Narayan Gautam.
Associate Professor, Department of Biochemistry, Universal College of Medical Sciences, Bhairahawa, Nepal
Article citation:
Gupta S, Jayan A, Jha AC, Gautam N. Frequency of glycemic control in Type 2 Diabetes Mellitus patients assessed by glycated hemoglobin and estimated average blood glucose. J Pharm Biomed Sci. 2015; 05(04):291-295. Available at www.jpbms.info
ABSTRACT:
Objective: To estimate HbA1c (%) in type 2 Diabetes mellitus (DM) patients to calculate estimated average blood glucose (eAG) and to correlate them with fasting and post prandial blood glucose level.
Materials and methods: HbA1c was estimated in hemolysate by nephelometric method followed by National Glycohemoglobin Standardization Program (NGSP) protocol with MISPA-I2 smart card system in 104 type 2 DM patients. FBG and PPBG were simultaneously determined in serum of patients. The calculation was done by using formula eAG (mg/dl): (28.7*HbA1c)-46.7 given by NSGP/DCCT guideline. The categorization of glycemic control was made as HbA1c ≤5.9% (very good glycemic control), HbA1c between 6.0 and 6.9 % (good glycemic control), HbA1c between 7.0 and 7.9 % (poor glycemic control), HbA1c ≥ 8% (bad glycemic control).
Results: The age-wise categorization of type 2 DM shows maximum frequency of patients of 21 (20.19 %) comprising 10 (9.61 %) male and 11(10.57 %) female respectively in age group 41-60 whose HbA1c and eAG were (7.6 ± 2.9 %) and eAG (172.66 ± 81.79 mg/dl) respectively. The statistically significant correlation was observed between HbA1c/eAG with FBG and PPBG (p<0.001).
Conclusion: The high frequency of patients in categories >8.0 % HbA1c and increased eAG signifies the bad glycemic control and project to the complication associated with DM later in life.
KEYWORDS: HbA1c; estimated average glucose; glycemic control; Type 2 DM.
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
REFERENCES
1.The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of Diabetes on the development and progression of long term complications in the diabetes control in insulin diabetes mellitus. N Engl J Med 1993; 329: 977-86.
2.Dahl-Jorghensen K, Brichmann-Hanssen O, Hansenn KF, et al. Effect of near normoglycemia for two years on progression of early diabetic retinopathy, nephropathy and neuropathy. The Oslo Study. Br Med J 1986; 293: 1195-9.
3.Lauritzen T, Forst-Larsen K, Larsen HV, Deckert T. Steno Study group: Two-year experience with continuous subcutaneous infusion in relation to retinopathy and nephropathy. Diabetes 1985; 34 (suppl. 3): 74-9.
4.Alan M. Delamater. Improving Patient Adherence. Clinical Diabetes 2006: 24 (1):71-77.
5.America Diabetes Association: Clinical practice recommendations (position statement). Diabetes care 2001; 24 (suppl.1) S33-S55.
6.Tietz NW. Textbook of Clinical Chemistry, Philadelphia WB. Saunders Company 1999: 794-795.
7.Nathan DM, Kuenen J, Borg R et al. Translating the HbA1c assay into estimated average glucose values. Diabetes Care 2008; 31:1-6.
8.Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality: The San Antonio Heart Study. Diabetes Care 1998; 21:1167–1172.
9.Singer DE, Nathan DM, Anderson KM, Wilson PWF, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-208.
10.Rohlfing CL, Wiedmeyer HM et al. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002; 25(2): 275-8.
11.Engelgau M M, Thompson TJ et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20(5): 785-91.
12.International Diabetes Federation (IDF) Diabetes Atlas: Sixth edition 2013:108.
13.Khaw KT, Wareham N et al. Glycated haemoglobin, Diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001; 322(7277): 15-8.
14.Grant, T., Y. Soriano, et al. (2004). Community-based screening for cardiovascular disease and diabetes using HbA1c. Am J Prev Med 2004; 26(4): 271-5.
15.Héctor García-Alcalá, Alejandro Ruiz-Argüelles, Beatriz Cedillo-Carvallo. Comparison of an Immunoassay with High-Performance Liquid Chromatography Am J Clin Pathol 2009; 132:332-335.
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Gupta S, Jayan A, Jha AC, Gautam N. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article
Zheng Liu, Haiyun Chen, Fangcheng Luo, Baojian Guo, Xiaoyong Jing, Zaijun Zhang, Yewei Sun, Yuqiang Wang
Affiliation:
Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy, Guangzhou 510632 China
The name of the department(s) and institution(s) to which the work should be attributed:
Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy, Guangzhou 510632, China
Address reprint requests to
* Pei Yu, PhD,
Institute of New Drug Research and Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine, Jinan University College of Pharmacy, Guangzhou 510632 China or at pennypeiyu@163.com. Tel.: +8620-8522-5030; Fax: +8620-8522-5030
Article citation:
Zheng L, Haiyun C, Fangcheng L, Baojian G, Xiaoyong J, Zaijun Z et al. Probe to Bifunctional Memantine Derivatives for Treatment of Alzheimer's Disease. J Pharm Biomed Sci. 2015; 05(04):276-290. Available at www.jpbms.info
ABSTRACT:
Alzheimer’ disease (AD) is a neurodegenerative disease commonly occurring in older people. Two types of drugs, the acetylcholinesterase (AChE) inhibitor and the N-methyl-D-aspartate receptor (NMDAR) antagonist, were approved to treat AD by FDA. Of them, memantine was the only one of NMDAR antagonist. Previous studies had revealed that the carbamate grouphad a better AChE inhibitor activity. Herein, a series of new memantine derivatives with a carbamate group were designed and synthesized. They were expected to haveboth NMDAR antagonism and AChE inhibition. However, the neuroprotective effect of these new compounds against the glutamate-induced neurotoxicity was not as effective as memantine. The AChE inhibition of them wasalso lower than tacrine. The combine of memantine moiety and carbamate group attenuated the activities of the two functional groups. It may be caused by the changes of the spatial structures after combination. The introduction of large spatial structures makes the functional groups difficult to orientate to the active site.
KEYWORDS: Acetylcholinesterase (AChE) inhibitor; Alzheimer’s disease (AD); Memantine derivatives; Multi-functional drugs; NMDAR antagonist..
Statement of Originality of work: The manuscript has been read and approved by all the authors, the requirements for authorship have been met, and that each author believes that the manuscript represents honest and original work.
ACKNOWLEDGEMENTS
This work was supported partially by The Natural Science Foundation of Guangdong Province (2014A030320174).
REFRENCES
1.Prince M, Bryce R, Ferri C. World Alzheimer Report 2011: The benefits of early diagnosis and intervention: Alzheimer's Disease International; 2011.
2.Association As. 2012 Alzheimer’s disease facts and figures. Alzheimer's & Dementia. 2012;8(2):131-68.
3.Alonso AC, Li B, Grundke-Iqbal I, Iqbal K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2008;5(4):375-84.
4.Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends pharmaco sci. 1991;12:383-8.
5.Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends in neurosciences. 1999;22(6):273-80.
6.Pimentel C, Batista NL, Rodrigues PC, Menezes RA. Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae. Oxidative medicine and cellular longevity. 2012;2012.
7.Francis PT. Glutamatergic systems in Alzheimer's disease. International journal of geriatric psychiatry. 2003;18(S1):S15-S21.
8.Maragos WF, Greenamyre JT, Penney JB, Young AB. Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends in neurosciences. 1987;10(2):65-8.
9.Tsai VW, Scott HL, Lewis RJ, Dodd PR. The role of group I metabotropic glutamate receptors in neuronal excitotoxicity in Alzheimer’s disease. Neurotoxicity research. 2005;7(1-2):125-41.
10.Wenk GL. Neuropathologic changes in Alzheimer's disease: potential targets for treatment. Journal of Clinical Psychiatry. 2006;67:3.
11.Johnson JW, Kotermanski SE. Mechanism of action of memantine. Current opinion in pharmacology. 2006;6(1):61-7.
12.Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. International journal of geriatric psychiatry. 2012;27(8):769-76.
13.Witt A, Macdonald N, Kirkpatrick P. Memantine hydrochloride. Nature Reviews Drug Discovery. 2004;3(2):109-10.
14.Chen H, Wang Y, Rayudu P, Edgecomb P, Neill J, Segal M, et al. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 1998;86(4):1121-32.
15.Chen HS, Lipton SA. The chemical biology of clinically tolerated NMDA receptor antagonists. Journal of neurochemistry. 2006;97(6):1611-26.
16.Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clinical therapeutics. 2004;26(5):615-30.
17.Mahlberg R, Walther S, Eichmann U, Tracik F, Kunz D. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. Archives of gerontology and geriatrics. 2007;45(1):19-26.
18.Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Journal of medicinal chemistry. 2002;45(24):5260-79.
19.Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ open. 2012;2(3):e000917.
20.Marutani E, Kosugi S, Tokuda K, Khatri A, Nguyen R, Atochin DN, et al. A novel hydrogen sulfide-releasing N-methyl-D-aspartate receptor antagonist prevents ischemic neuronal death. Journal of Biological Chemistry. 2012;287(38):32124-35.
21.Simoni E, Daniele S, Bottegoni G, Pizzirani D, Trincavelli ML, Goldoni L, et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer’s disease. Journal of medicinal chemistry. 2012;55(22):9708-21. 22.Sozio P, Cerasa LS, Laserra S, Cacciatore I, Cornacchia C, Di Filippo ES, et al. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer’s disease. European Journal of Pharmaceutical Sciences. 2013;49(2):187-98.
23.Youdim MB. Why Do We Need Multifunctional Neuroprotective and Neurorestorative Drugs for Parkinson’s and Alzheimer’s Disorders? Rambam Maimonides Medical Journal. 2010;1(2).
24.Cui W, Zhang Z, Li W, Hu S, Mak S, Zhang H, et al. The anti‐cancer agent SU4312 unexpectedly protects against MPP+‐induced neurotoxicity via selective and direct inhibition of neuronal NOS. British journal of pharmacology. 2013;168(5):1201-14.
25.Fu H, Li W, Lao Y, Luo J, Lee NT, Kan KK, et al. Bis (7)‐tacrine attenuates β amyloid‐induced neuronal apoptosis by regulating L‐type calcium channels. Journal of neurochemistry. 2006;98(5):1400-10.
26. Ellman GL, Courtney KD, Andres jr V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology. 1961;7(2):88-95.
27.Sanner MF. Python: a programming language for software integration and development. Journal of molecular graphics & modelling. 1999;17(1):57-61.
28.Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of computational chemistry. 2010;31(2):455-61.
29.Huang CC, Couch GS, Pettersen EF, Ferrin TE, editors. Chimera: an extensible molecular modeling application constructed using standard components. Pacific symposium on biocomputing; 1996.
30.SchuÈttelkopf AW, Van Aalten DM. PRODRG: a tool for high-throughput crystallography of protein–ligand complexes. Acta Crystallographica Section D: Biological Crystallography. 2004;60(8):1355-63.
31.Harel M, Schalk I, Ehret-Sabatier L, Bouet F, Goeldner M, Hirth C, et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(19):9031-5.
32.Bernstein FC, Koetzle TF, Williams GJ, Meyer EF, Brice MD, Rodgers JR, et al. The protein data bank. European Journal of Biochemistry. 1977;80(2):319-24.
33.Mehta DC, Short JL, Nicolazzo JA. Memantine Transport across the Mouse Blood–Brain Barrier Is Mediated by a Cationic Influx H+ Antiporter. Molecular pharmaceutics. 2013;10(12):4491-8.
34.Henkel JG, Hane JT, Gianutsos G. Structure-anti-Parkinson activity relationships in the aminoadamantanes. Influence of bridgehead substitution. Journal of medicinal chemistry. 1982;25(1):51-6.
35.Wang Y, Ye W, Larrick JW, Stemler JS, Lipton SA. Aminoadamantane derivatives as therapeutic agents. Google Patents; 2008.
36.Klimova N, Lavrova N, Zaitseva N, Pyatin B, Morozov I, Bykov N, et al. Hydroxyladamantanes and their biological activity. Khimiko-farmatsevticheskii Zhurnal 1986;20(7):810-5.
37.Cai X, Hu W, Yao Z. Preparation of rimantadine hydrochloride. Chinese journal of medicinal chemistry. 2002;12(3):161-3.
38.Jimenez HN, Li G, Doller D, Grenon M, White AD, Ma G, et al. Adamantyl diamide derivatives and uses of same. Google Patents; 2011.
39.Wang Y, Ye W, Larrick J, Stamler J, Lipton S. Aminoadamantane derivatives as therapeutic agents. Google Patents; 2002.
40.Luo J, Li W, Zhao Y, Fu H, Ma DL, Tang J, et al. Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis (propyl)-cognitin. Journal of Biological Chemistry. 2010;285(26):19947-58.
41.Lipton SA. Pathologically activated therapeutics for neuroprotection. Nature Reviews Neuroscience. 2007;8(10):803-8.
42.Xia P, Chen H-sV, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. The Journal of Neuroscience. 2010;30(33):11246-50.
43.Farlow MR, Evans RM. Pharmacologic treatment of cognition in Alzheimer's dementia. Neurology. 1998;51(1 Suppl 1):S36-S44.
44.Whitehouse PJ. Cholinergic therapy in dementia. Acta Neurologica Scandinavica. 1993;88(S149):42-5.
45.Ma HJ, Xie RL, Zhao QF, Mei XD, Ning J. Synthesis and insecticidal activity of novel carbamate derivatives as potential dual-binding site acetylcholinesterase inhibitors. Journal of agricultural and food chemistry. 2010;58(24):12817-21.
46.Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol. 2000;22(8):609-13.
47.Bin H, Ao GZ, Shi LL, Yu J. Synthesis of Memantine Hydrochloride. Chinese Journal of Pharmaceuticals. 2009;4:008.
48.Yong Z, Xiao X, Qi M. Synthesis of Memantine Hydrochloride. Chinese Journal of Pharmaceuticals. 2003.
49.Cai XH HW, Yao ZF, Liu ZH. Preparation of rimantadine hydrochloride. Chinese Journal of Medicinal Chemistry. 2002;12:161-3.
50.Wanka L, Cabrele C, Schreiner PR, Vanejews M. γ-Aminoadamantanecarboxylic Acids Through Direct C–H Bond Amidations. European Journal of Organic Chemistry. 2007;2007(9):1474–90.
51.Samnick S, Ametamey S, Gold MR, Schubiger PA. Synthesis and preliminary in vitro evaluation of a new memantine derivative 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane: A potential ligand for mapping the N-methyl-D-aspartate receptor complex. Journal of Labelled Compounds and Radiopharmaceuticals. 1997;39(3):241–50..
Source of support: This work was supported partially by The Natural Science Foundation of Guangdong Province (2014A030320174)
Disclaimer: Any views expressed in this paper are those of the authors and do not reflect the official policy or position of the Department of Defense.
Copyright © 2015 Zheng L, Haiyun C, Fangcheng L, Baojian G, Xiaoyong J, Zaijun Z et al. This is an open access article under the CCBY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/). Which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.